当前位置: 首页 >> 检索结果
641. RESCUE-AF in Patients Undergoing Atrial Fibrillation Ablation: The RESCUE-AF Trial.
作者: Xi Zhang.;Xiaohui Kuang.;Xiaolong Gao.;Hong Xiang.;Feiyu Wei.;Tong Liu.;Haiyan Wu.;Gang Wang.;Zan Zuo.;Lilin Wang.;Liqun Ding.;Jin Zhang.;Michael Shehata.;Xunzhang Wang.;Bing Yang.;Jie Fan.
来源: Circ Arrhythm Electrophysiol. 2019年12卷5期e007044页
Although contact force (CF)–sensing catheters improve procedural effectiveness and safety of atrial fibrillation ablation, recent reports documented a higher incidence of atrioesophageal fistula formation relative to ablation with non–CF-sensing catheters.The present study was to assess whether restricting CF to <20 g reduced risk for esophageal injury (EI) in patients with atrial fibrillation undergoing circumferential pulmonary vein isolation.
642. Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation: Insights From Patients at Risk Monitored Long Term With an Implantable Loop Recorder.
作者: Søren Zöga Diederichsen.;Ketil Jørgen Haugan.;Christian Kronborg.;Claus Graff.;Søren Højberg.;Lars Køber.;Derk Krieger.;Anders Gaarsdal Holst.;Jonas Bille Nielsen.;Axel Brandes.;Jesper Hastrup Svendsen.
来源: Circulation. 2020年141卷19期1510-1522页
Stroke is an increasing health problem worldwide. Atrial fibrillation (AF) is a major risk factor for stroke, and the attention given to AF screening is rising, as new monitoring technologies emerge. We aimed to evaluate the performance of a large panel of screening strategies and to assess population characteristics associated with diagnostic yield.
643. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
作者: M Angelyn Bethel.;Susanna R Stevens.;John B Buse.;Jasmine Choi.;Stephanie M Gustavson.;Nayyar Iqbal.;Yuliya Lokhnygina.;Robert J Mentz.;Rishi A Patel.;Peter Öhman.;Guntram Schernthaner.;Albert Lecube.;Adrian F Hernandez.;Rury R Holman.
来源: Circulation. 2020年141卷17期1360-1370页
EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2 diabetes mellitus, while aiming for glycemic equipoise. Consequently, greater drop-in of open-label glucose-lowering medications occurred in the placebo group. Accordingly, we explored the potential effects of their unbalanced use on major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, and all-cause mortality (ACM), given that some of these agents are cardioprotective.
644. Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis: A Serial Optical Coherence Tomography Study.
作者: Yasushi Ueki.;Lorenz Räber.;Tatsuhiko Otsuka.;Himanshu Rai.;Sylvain Losdat.;Stephan Windecker.;Hector M Garcia-Garcia.;Ulf Landmesser.;Jacques Koolen.;Robert Byrne.;Michael Haude.;Michael Joner.
来源: Circ Cardiovasc Interv. 2020年13卷3期e008657页
The pathomechanisms underlying restenosis of the bioabsorbable sirolimus-eluting metallic scaffold (Magmaris) remain unknown. Using serial optical coherence tomography, we investigated causes of restenosis, including the contribution of late scaffold recoil versus neointimal hyperplasia.
645. The Prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence-Based Approach Using Perfusion Mapping.
作者: Kristopher D Knott.;Andreas Seraphim.;Joao B Augusto.;Hui Xue.;Liza Chacko.;Nay Aung.;Steffen E Petersen.;Jackie A Cooper.;Charlotte Manisty.;Anish N Bhuva.;Tushar Kotecha.;Christos V Bourantas.;Rhodri H Davies.;Louise A E Brown.;Sven Plein.;Marianna Fontana.;Peter Kellman.;James C Moon.
来源: Circulation. 2020年141卷16期1282-1291页
Myocardial perfusion reflects the macro- and microvascular coronary circulation. Recent quantitation developments using cardiovascular magnetic resonance perfusion permit automated measurement clinically. We explored the prognostic significance of stress myocardial blood flow (MBF) and myocardial perfusion reserve (MPR, the ratio of stress to rest MBF).
646. One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention: The T-TIME Randomized Trial.
作者: Annette M Maznyczka.;Peter J McCartney.;Hany Eteiba.;John P Greenwood.;Douglas F Muir.;Saqib Chowdhary.;Anthony H Gershlick.;Clare Appleby.;James M Cotton.;Andrew Wragg.;Nick Curzen.;Keith G Oldroyd.;Mitchell Lindsay.;Margaret McEntegart.;J Paul Rocchiccioli.;Aadil Shaukat.;Richard Good.;Stuart Watkins.;Keith Robertson.;Christopher Malkin.;Lynn Martin.;Lynsey Gillespie.;Robin A Weir.;Thomas J Ford.;Mark C Petrie.;Aengus Murphy.;Colin J Petrie.;Nitish Ramparsad.;Kirsty Wetherall.;Keith A Fox.;Ian Ford.;Alex McConnachie.;Colin Berry.; .
来源: Circ Cardiovasc Interv. 2020年13卷2期e008855页 647. Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China.
作者: Shijun Xia.;Xin Du.;Lizhu Guo.;Jing Du.;Clare Arnott.;Carolyn S P Lam.;Mark D Huffman.;Hisatomi Arima.;Yiqiang Yuan.;Yang Zheng.;Shulin Wu.;Xuefeng Guang.;Xianhui Zhou.;Hongbo Lin.;Xiaoshu Cheng.;Craig S Anderson.;Jianzeng Dong.;Changsheng Ma.
来源: Circulation. 2020年141卷7期530-539页
Despite improvements in diagnostic and therapeutic interventions to combat cardiovascular disease (CVD) in recent decades, there are significant ongoing access gaps and sex disparities in prevention that have not been adequately quantified in China.
648. Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial.
作者: Jessica M Scott.;Samantha M Thomas.;Jeffrey M Peppercorn.;James E Herndon.;Pamela S Douglas.;Michel G Khouri.;Chau T Dang.;Anthony F Yu.;Diane Catalina.;Cristi Ciolino.;Catherine Capaci.;Meghan G Michalski.;Neil D Eves.;Lee W Jones.
来源: Circulation. 2020年141卷7期560-570页
Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise programming that has received minimal attention is dose scheduling. We investigated the tolerability and efficacy of 2 exercise training dose regimens on cardiorespiratory fitness and patient-reported outcomes in patients with posttreatment primary breast cancer.
649. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
作者: Farzin Khosrow-Khavar.;Kristian B Filion.;Nathaniel Bouganim.;Samy Suissa.;Laurent Azoulay.
来源: Circulation. 2020年141卷7期549-559页
The association between aromatase inhibitors and cardiovascular outcomes among women with breast cancer is controversial. Given the discrepant findings from randomized controlled trials and observational studies, additional studies are needed to address this safety concern.
650. Body Mass Index in Young Women and Risk of Cardiomyopathy: A Long-Term Follow-Up Study in Sweden.
作者: Josefina Robertson.;Martin Lindgren.;Maria Schaufelberger.;Martin Adiels.;Lena Björck.;Christina E Lundberg.;Naveed Sattar.;Annika Rosengren.;Maria Åberg.
来源: Circulation. 2020年141卷7期520-529页
Incidence rates of cardiomyopathies, which are a common cause of heart failure in young people, have increased during the last decades. An association between body weight in adolescence and future cardiomyopathy among men was recently identified. Whether or not this holds true also for women is unknown. The aim was therefore to determine whether for young women being overweight or obese is associated with a higher risk of developing cardiomyopathy.
651. Deep Learning-Based Quantification of Epicardial Adipose Tissue Volume and Attenuation Predicts Major Adverse Cardiovascular Events in Asymptomatic Subjects.
作者: Evann Eisenberg.;Priscilla A McElhinney.;Frederic Commandeur.;Xi Chen.;Sebastien Cadet.;Markus Goeller.;Aryabod Razipour.;Heidi Gransar.;Stephanie Cantu.;Robert J H Miller.;Piotr J Slomka.;Nathan D Wong.;Alan Rozanski.;Stephan Achenbach.;Balaji K Tamarappoo.;Daniel S Berman.;Damini Dey.
来源: Circ Cardiovasc Imaging. 2020年13卷2期e009829页
Epicardial adipose tissue (EAT) volume (cm3) and attenuation (Hounsfield units) may predict major adverse cardiovascular events (MACE). We aimed to evaluate the prognostic value of fully automated deep learning-based EAT volume and attenuation measurements quantified from noncontrast cardiac computed tomography.
652. SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation.
作者: Alok Kapoor.;Azraa Amroze.;Fatima Vakil.;Sybil Crawford.;Jacqueline Der.;Jomol Mathew.;Eric Alper.;Dinesh Yogaratnam.;Saud Javed.;Rasha Elhag.;Abraham Lin.;Siddhartha Narayanan.;Donna Bartlett.;Ahmed Nagy.;Bevin Kathleen Shagoury.;Michael A Fischer.;Kathleen M Mazor.;Jane S Saczynski.;Jeffrey M Ashburner.;Renato Lopes.;David D McManus.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷2期e005871页
Previous provider-directed electronic messaging interventions have not by themselves improved anticoagulation use in patients with atrial fibrillation. Direct engagement with providers using academic detailing coupled with electronic messaging may overcome the limitations of the prior interventions.
653. Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.
作者: Faisal Latif.;Lauren Uyeda.;Robert Edson.;Deepak L Bhatt.;Steven Goldman.;David R Holmes.;Sunil V Rao.;Kendrick Shunk.;Kul Aggarwal.;Barry Uretsky.;Islam Bolad.;Khaled Ziada.;Edward McFalls.;Anand Irimpen.;Huu Tam Truong.;Scott Kinlay.;Vasilios Papademetriou.;Raghava S Velagaleti.;Bavana V Rangan.;Kreton Mavromatis.;Mei-Chiung Shih.;Subhash Banerjee.;Emmanouil S Brilakis.
来源: Circ Cardiovasc Interv. 2020年13卷2期e008494页
Direct stenting without pre-dilation or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal embolization, periprocedural myocardial infarction, and target lesion revascularization.
654. Preventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trial.
作者: Stephan Willems.;Roland Richard Tilz.;Daniel Steven.;Stefan Kääb.;Karl Wegscheider.;László Gellér.;Christian Meyer.;Christian-Hendrik Heeger.;Andreas Metzner.;Moritz F Sinner.;Michael Schlüter.;Peter Nordbeck.;Lars Eckardt.;Harilaos Bogossian.;Arian Sultan.;Beate Wenzel.;Karl-Heinz Kuck.; .
来源: Circulation. 2020年141卷13期1057-1067页
Catheter ablation for ventricular tachycardia (VT) reduces the recurrence of VT in patients with implantable cardioverter-defibrillators (ICDs). The appropriate timing of VT ablation and its effects on mortality and heart failure progression remain a matter of debate. In patients with life-threatening arrhythmias necessitating ICD implantation, we compared outcomes of preventive VT ablation (undertaken before ICD implantation to prevent ICD shocks for VT) and deferred ablation after 3 ICD shocks for VT.
655. Effects of Omega-3 Fatty Acid Supplements on Arrhythmias.
作者: Sarah Parish.;Marion Mafham.;Alison Offer.;Jill Barton.;Karl Wallendszus.;William Stevens.;Georgina Buck.;Richard Haynes.;Rory Collins.;Louise Bowman.;Jane Armitage.; .
来源: Circulation. 2020年141卷4期331-333页 656. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
作者: Peder L Myhre.;Muthiah Vaduganathan.;Eileen O'Meara.;Brian L Claggett.;Simon de Denus.;Petr Jarolim.;Inder S Anand.;Bertram Pitt.;Jean L Rouleau.;Scott D Solomon.;Marc A Pfeffer.;Akshay S Desai.
来源: Circ Heart Fail. 2020年13卷1期e006638页
Spironolactone has been demonstrated to reduce heart failure (HF) hospitalization in patients with HF with preserved ejection fraction in the Americas region of the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial). We assessed effects of 12 months of treatment with spironolactone on biomarkers reflecting myocardial stress, myocardial injury, renal function, and systemic inflammation.
657. RADAR: A Multicenter Food and Drug Administration Investigational Device Exemption Clinical Trial of Persistent Atrial Fibrillation.
作者: Subbarao Choudry.;Moussa Mansour.;Sri Sundaram.;Duy T Nguyen.;Srinivas R Dukkipati.;William Whang.;Paul Kessman.;Vivek Y Reddy.
来源: Circ Arrhythm Electrophysiol. 2020年13卷1期e007825页
Pulmonary vein isolation is insufficient to treat all patients with persistent atrial fibrillation (AF), and effective adjunctive ablation strategies are needed. Ablation of AF drivers holds promise, but current technologies to identify drivers are limited by spatial resolution. In a single-arm, first-in-human, investigator-initiated Food and Drug Administration Investigational Device Exemption study, we used a novel system for real-time, high-resolution identification of AF drivers in persistent AF.
658. An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition.
作者: Jason D Roberts.;S Yukiko Asaki.;Andrea Mazzanti.;J Martijn Bos.;Izabela Tuleta.;Alison R Muir.;Lia Crotti.;Andrew D Krahn.;Valentina Kutyifa.;M Benjamin Shoemaker.;Christopher L Johnsrude.;Takeshi Aiba.;Luciana Marcondes.;Anwar Baban.;Sharmila Udupa.;Brynn Dechert.;Peter Fischbach.;Linda M Knight.;Eric Vittinghoff.;Deni Kukavica.;Birgit Stallmeyer.;John R Giudicessi.;Carla Spazzolini.;Keiko Shimamoto.;Rafik Tadros.;Julia Cadrin-Tourigny.;Henry J Duff.;Christopher S Simpson.;Thomas M Roston.;Yanushi D Wijeyeratne.;Imane El Hajjaji.;Maisoon D Yousif.;Lorne J Gula.;Peter Leong-Sit.;Nikhil Chavali.;Andrew P Landstrom.;Gregory M Marcus.;Sven Dittmann.;Arthur A M Wilde.;Elijah R Behr.;Jacob Tfelt-Hansen.;Melvin M Scheinman.;Marco V Perez.;Juan Pablo Kaski.;Robert M Gow.;Fabrizio Drago.;Peter F Aziz.;Dominic J Abrams.;Michael H Gollob.;Jonathan R Skinner.;Wataru Shimizu.;Elizabeth S Kaufman.;Dan M Roden.;Wojciech Zareba.;Peter J Schwartz.;Eric Schulze-Bahr.;Susan P Etheridge.;Silvia G Priori.;Michael J Ackerman.
来源: Circulation. 2020年141卷6期429-439页
Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration.
659. Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested Case-Control Study.
作者: María Trinidad Soria-Florido.;Olga Castañer.;Camille Lassale.;Ramon Estruch.;Jordi Salas-Salvadó.;Miguel Ángel Martínez-González.;Dolores Corella.;Emilio Ros.;Fernando Arós.;Roberto Elosua.;José Lapetra.;Miquel Fiol.;Angel Alonso-Gómez.;Enrique Gómez-Gracia.;Lluís Serra-Majem.;Xavier Pintó.;Mònica Bulló.;Miguel Ruiz-Canela.;Jose V Sorlí.;Álvaro Hernáez.;Montserrat Fitó.
来源: Circulation. 2020年141卷6期444-453页
Studies have failed to establish a clear link between high-density lipoprotein (HDL) cholesterol and cardiovascular disease, leading to the hypothesis that the atheroprotective role of HDL lies in its biological activity rather than in its cholesterol content. However, to date, the association between HDL functional characteristics and acute coronary syndrome has not been investigated comprehensively.
660. Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest.
作者: Mohamud R Daya.;Brian G Leroux.;Paul Dorian.;Thomas D Rea.;Craig D Newgard.;Laurie J Morrison.;Joshua R Lupton.;James J Menegazzi.;Joseph P Ornato.;George Sopko.;Jim Christenson.;Ahamed Idris.;Purav Mody.;Gary M Vilke.;Caroline Herdeman.;David Barbic.;Peter J Kudenchuk.; .
来源: Circulation. 2020年141卷3期188-198页
Antiarrhythmic drugs have not proven to significantly improve overall survival after out-of-hospital cardiac arrest from shock-refractory ventricular fibrillation/pulseless ventricular tachycardia. How this might be influenced by the route of drug administration is not known.
|